Reading Your Response Report: The Four Verdicts
"Partial response" can sound like failure until you learn the math; "stable" can sound like stagnation until you learn the game. The categories make sense the moment you see what they are actually measuring.
Response categories — complete (disappearance), partial (≥30% shrinkage), stable (neither threshold crossed), and progressive (≥20% growth or new lesions) — are standardized verdicts that tell your team whether treatment is winning, holding, or losing. They ride on measurements plus metabolism plus your symptoms, and they come with famous traps: pseudoprogression can mimic failure early in immunotherapy when treatment is actually working.
What do the four response categories mean?
| Verdict | Definition | What it usually means |
|---|---|---|
| Complete response | All target lesions gone | Imaging shows no tumor — surveillance begins |
| Partial response | ≥30% shrinkage | Treatment is winning — often the realistic goal |
| Stable disease | Between −30% and +20% | Holding ground — a legitimate, valuable outcome |
| Progressive disease | ≥20% growth or new lesions | Treatment is losing — time to regroup |
Stable disease, in particular, is not "nothing happened" — for many cancers and many lines of therapy, holding the line is the win that extends life with quality.
Why do scans overstate or understate the truth?
Pseudoprogression: immunotherapy can inflame tumors before shrinking them — early scans look worse while treatment works. Guidelines now require confirmatory scans before declaring progression on immunotherapy, precisely because abandoning a working drug is the costliest mistake in modern oncology. Pseudoresponse runs the other way: anti-angiogenic drugs can quiet a tumor's enhancement and swelling while viable cancer persists — MRI reads "better" while biology disagrees. Both traps are why the verdict never rides on images alone.
What completes the response picture beyond scans?
- Tumor markers: falling CA-125, AFP, PSA corroborate; rising ones interrogate
- Symptoms and function: pain, appetite, weight, energy — the patient-reported endpoint
- Metabolic imaging (PET): sugar-hunger responds before size
- Timing and trajectory: one scan is a snapshot; the trend is the story
How should I read my own response report?
- Find the category word — complete, partial, stable, progressive — in the impression
- Compare to the last scan, not to the first — trajectories bend
- Check for new lesions — the category-changer
- Read the metabolic sentence if PET was done — it often disagrees with size first
- Bring your symptoms — the discordance conversation is where good oncology lives
What does a "progressive" report actually trigger?
Not doom — a regroup: biopsy of a progressing site when the type matters (resistant clones differ), biomarker and mutation retesting (new targets emerge), and the next-line conversation — which in modern oncology often has a next line, and another after that. Progressive disease on one line of therapy is a turning point in a long war, not its end; patients who understand the category as information rather than verdict navigate the turn far better.
Decoding a response report?
Ask our team — then bring your symptoms to the oncologist.
Contact SATMED HealthFrequently asked questions about treatment response
Is stable disease good or bad news?
Good — it means treatment is holding the cancer. For many cancers and therapies, stable disease is the realistic win that preserves quality of life.
What is pseudoprogression?
Immunotherapy inflaming tumors before shrinking them — early scans look worse while the treatment works. Confirmatory scans before declaring progression are now standard.
Can a tumor respond without shrinking?
Yes — metabolic activity and enhancement fall before size; functional imaging often reads response earlier than calipers.
What does partial response mean for survival?
It means the treatment is working — and in modern oncology, partial responses can be durable, conversion-enabling, and survival-extending.
Should I ask for a second opinion on a progression call?
On immunotherapy, or when the call changes treatment — reasonable; confirmatory scans and expert review are built into guidelines for exactly these moments.
Do response categories apply to every cancer?
They are designed for solid tumors; blood cancers use their own systems (which is why lymphoma reports sound different).
How SATMED Health makes contrast imaging safer
If your exam includes contrast, the delivery equipment matters as much as the scanner. SATMED Health engineers the systems behind every injection.
Contrast injector systems built for controlled, consistent delivery — the right dose at the right moment, every time.
Learn more →Engineered syringes for smooth, low-pressure injections that reduce discomfort and protect the vessel at the IV site.
Learn more →Patient lines and accessories designed for safe, reliable contrast administration from injector to vein.
Learn more →Contrast management solutions that help departments prepare, verify, and track every dose before it reaches a patient.
Learn more →Keep reading
More free, clinician-reviewed guides from SATMED Health.
Sources
- RadiologyInfo.org (ACR · RSNA · ASRT). PET/CT. Reviewed June 15, 2026.
- RadiologyInfo.org (ACR · RSNA · ASRT). Body CT. Reviewed June 15, 2026.
- American College of Radiology. ACR Accredited Facilities Database.
Categories are information, not verdicts
Browse more free imaging guides or reach out with any question.
Contact SATMED HealthMedical disclaimer: This article is for education only and is not medical advice, diagnosis, or treatment. Always follow the instructions of your imaging facility and your own physician. If you think you are having an emergency, call 911 (or your local emergency number) immediately.
Please note: SATMED Health is not a medical facility. Please contact your physician with specific medical questions or for a referral to a radiologist. To locate an accredited medical imaging provider in your community, search the ACR accredited facilities database. This website does not provide cost information; imaging costs vary by region.
